Results 131 to 140 of about 3,281 (174)

Immune-related pancytopenia in pregnancy. [PDF]

Intern Med J
Su Z, Xu J, Cui H.
europepmc   +1 more source

Multiome-based identification of molecular markers for prospective identification of platelet-biased HSCs. [PDF]

Stem Cell Reports
Zhang B, Meng Y, Correa ER, Ren X, Fagnan A, Milsom MD, Nerlov C.   +6 more
europepmc   +1 more source

Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study. [PDF]

Cancers (Basel)
Joffe E, Epstein-Peterson Z, Falchi L, Noy A, Zelenetz AD, Owens C, Gilbert L, Salles G, Soff GA.   +8 more
europepmc   +1 more source

Utility and Safety of Romiplostim in Pediatric Allogeneic Stem Cell Transplantation. [PDF]

Pediatr Transplant
Senthil S, Moothedath A, Potter JE, Wilkinson HM, Whiteside E, Nataraj R, Mustafa O, Horgan C, Bonney D, Brett S, Wynn R.   +10 more
europepmc   +1 more source

Successful Management of Relapsed Severe Immune Thrombocytopenia Using Avatrombopag: A Case Report. [PDF]

Case Rep Hematol
Almutairi S, Warsi A, Hejazi A, Melibari E, Jar R, Almutairi A, Abughasham A, Firaque N.   +7 more
europepmc   +1 more source

Primary Immune Thrombocytopenia (ITP) Treated With Romiplostim in Routine Clinical Practice: Retrospective Study From the United Kingdom ITP Registry

European Journal of Haematology, 2019
Background Romiplostim is a thrombopoietin‐mimetic peptibody for adult refractory chronic immune thrombocytopenia (ITP). We aimed to describe ITP patients receiving romiplostim, platelet counts and romiplostim usage in UK clinical practice.
Sandrine Leroy, Drew Provan, Adrian Newland   +2 more
exaly   +4 more sources

Evaluation of Bone Marrow Reticulin Formation in Chronic Immune Thrombocytopenia Patients Treated With Romiplostim

Blood, 2009
Romiplostim is a thrombopoietin receptor agonist that increases platelet counts in patients with chronic immune thrombocytopenia (ITP). Thrombopoietin receptor agonists are reported to increase the risk for reticulin fiber deposition within bone marrow ...
Robert Paul Hasserjian, David John Kuter, Barbara J Bain   +2 more
exaly   +2 more sources

Romiplostim for Management of Chemotherapy-Induced Thrombocytopenia

Supportive Care in Cancer, 2014
Purpose Chemotherapy-induced thrombocytopenia (CIT) can cause delay or reduction in subsequent courses of chemotherapy. Here, we report on a series of 20 patients who had protracted CIT and were treated with romiplostim, a thrombopoietin receptor agonist.
S Devlin, G Schwartz
exaly   +2 more sources